vidarabine has been researched along with Granulocytic Leukemia, Chronic in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (22.58) | 18.2507 |
| 2000's | 35 (56.45) | 29.6817 |
| 2010's | 13 (20.97) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burger, J; Cortes, J; Estrov, Z; Ferrajoli, A; Jain, N; Jain, P; Kanagal-Shamanna, R; Kantarjian, H; Keating, MJ; Luthra, R; Nogueras González, GM; O'Brien, S; Quesada, A; Rozovski, U; Sanchez-Petitto, G; Sarwari, N; Tam, C; Thompson, PA; Wierda, WG | 1 |
| Abuelgasim, KA; Al Atwi, N; Al Balwi, M; Almughairi, A; Alshieban, S; Alsubaie, M; Rehan, H | 1 |
| De Revel, T; Doghmi, K; Jennane, S; Konopacki, J; Mahtat, el M; Malfuson, JV; Mikdame, M | 1 |
| Abe, M; Fukuda, S; Kanai, R; Katsube, Y; Mishima, S; Ogushi, H; Tadokoro, M; Taketani, T; Yamaguchi, S; Yuba, S | 1 |
| Hiroshima, Y; Ichikawa, N; Kirihara, T; Kobayashi, H; Kurihara, T; Mori, Y; Sato, K; Shibazaki, M; Sumi, M; Takeda, W; Ueki, T; Ueno, M | 1 |
| Alatrash, G; Alousi, AM; Andersson, BS; Champlin, RE; Chen, J; de Lima, M; Fox, PS; Garber, HR; Hosing, C; Janbey, S; Jones, RB; Kebriaei, P; Ning, J; Popat, U; Rondon, G; Shpall, EJ; Thall, PF; Valdez, BC; Worth, LL | 1 |
| Non, LR; Pande, A; Romee, R; Santos, CA | 1 |
| Aloyz, R; Amrein, L; Ferrario, C; Gibson, SB; Hernandez, TA; Johnston, J; Panasci, L | 1 |
| Eyzaguirre-Zapata, R; Gómez-Almaguer, D; González-Carrillo, ML; Gutiérrez-Aguirre, CH; Gutiérrez-Riveroll, KI; Priesca-Marin, M; Ruiz-Argüelles, GJ; Ruiz-Delgado, GJ | 1 |
| Baran, Y; Bassoy, EY; Oztekin, C | 1 |
| Bauer, K; Engert, A; Kluge, S; Kreuzer, KA; Monsef, I; Siebert, H; Skoetz, N | 1 |
| Hattori, H; Karasuno, T; Kotake, T; Kuwayama, M | 1 |
| Calixto, R; Chandrasekaran, V; Domingues, MC; Florêncio, R; Maior, AP; Ostronoff, F; Ostronoff, M; Sucupira, A | 1 |
| Apperley, J; Foroni, L; Ibrahim, A; Marin, D; Milojkovic, D; Reid, A | 1 |
| Borthakur, G; Brandt, M; Burger, J; Cortes, J; Faderl, S; Gandhi, V; Garcia-Manero, G; Huang, X; Jabbour, E; Kadia, T; Kantarjian, H; Konopleva, M; O'Brien, S; Plunkett, W; Ravandi, F | 1 |
| Bolaños-Meade, J; Khanwani, SL; Sarkodee-Adoo, C | 1 |
| Ackerstein, A; Aker, M; Amar, A; Nagler, A; Naparstek, E; Or, R; Resnick, I; Samuel, S; Shapira, MY; Slavin, S | 1 |
| Baron, F; Beguin, Y; Fillet, G; Frère, P; Herens, C | 1 |
| Anasetti, C; Appelbaum, FR; Bornhauser, M; Deeg, HJ; Ehninger, G; Hansen, J; Jenke, A; Martin, PJ; McDonald, GB; Nichols, WG; Radich, J; Schleyer, E; Slattery, JT; Storer, B; Thiede, C; Woolfrey, A | 1 |
| Robak, T | 1 |
| Korycka, A; Robak, T | 2 |
| Okamoto, S | 1 |
| Bunjes, D; Döhner, H; Zenz, T | 1 |
| Barrett, AJ; Childs, RW; Greene, A; Sloand, E; Solomon, S; Young, NS | 1 |
| Giakoumi, X; Mantzouranis, M; Pangalis, GA; Vassilakopoulos, TP; Viniou, NA | 1 |
| Al-Ali, H; Brand, R; Deininger, M; Gentilini, C; Hegenbart, U; Krahl, R; Lange, T; Leiblein, S; Niederwieser, D; Petersdorf, E; Poenisch, W; Storb, RF; Uharek, L | 1 |
| Balleari, E; Ballerini, F; Balocco, M; Canepa, L; Clavio, M; Garrone, A; Gobbi, M; Michelis, GL; Miglino, M; Pierri, I; Venturino, C | 1 |
| Kolb, HJ; Ledderose, G; Rolf, B; Schleuning, M; Schnittger, S; Schoch, C; Schwerdtfeger, R; Weisser, M | 1 |
| Chan, ES; Linn, YC; Samuel, M; Tan, DC; Zhu, Q | 1 |
| Agura, E; Al-Ali, HK; Blume, KG; Bruno, B; Chauncey, TR; Epner, EM; Gooley, T; Hegenbart, U; Kerbauy, FR; Maloney, DG; Niederwieser, D; Radich, JP; Sandmaier, BM; Shizuru, J; Storb, R | 1 |
| Ahmed, P; Anwar, M; Hashmi, KU; Hussain, I; Iqbal, H; Khan, B; Mahmood, A; Malik, HS; Raza, S | 1 |
| Irving, I; Kennedy, GA; McCarthy, C; Perel, JM; Walker, O; Williams, B | 1 |
| Fiser, K; Klamová, H; Moravcová, J | 1 |
| Bornhäuser, M; Ehninger, G; Fruehauf, S; Kiehl, MG; Kienast, J; Kröger, N; Mundhenk, P; Sayer, HG; Schafer-Eckart, K; Scheid, C; Schwerdtfeger, R; Stelljes, M; Theuser, C; Wandt, H; Zander, AR | 1 |
| Ohnishi, K | 1 |
| Brychtova, Y; Dolezal, T; Doubek, M; Dvorakova, D; Horky, O; Koristek, Z; Krejci, M; Lengerova, M; Mayer, J; Pospisil, Z; Racil, Z; Vorlicek, J | 1 |
| Chuhjo, T; Kondo, Y; Kotani, T; Nakao, S; Ohtake, S; Okumura, H; Ozaki, J; Sugimori, C; Sugimori, N; Takami, A; Ueda, M; Yamaguchi, M; Yamazaki, H | 1 |
| Alousi, A; Anagnostopoulos, A; Anderlini, P; Carrasco-Yalan, A; Champlin, RE; Couriel, D; de Lima, M; Detry, MA; Giralt, S; Hosing, C; Kebriaei, P; Khouri, IF | 1 |
| Chen, MH; Chen, PM; Chiou, TJ; Gau, JP; Hsiao, LT; Hsu, HC; Lin, PC; Liu, JH | 1 |
| Dickmeiss, E; Heilmann, C; Jakobsen, B; Kornblit, B; Madsen, HO; Masmas, T; Olesen, G; Petersen, SL; Ryder, LP; Sengeløv, H; Svejgaard, A; Vindeløv, L | 1 |
| Casper, J; Freund, M; Giebel, S; Holowiecka-Goral, A; Holowiecki, J; Krawczyk-Kulis, M; Markiewicz, M; Wojnar, J | 1 |
| Lemoli, RM; Manfroi, S; Pelliconi, S; Rosti, G; Testoni, N; Tosi, P; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL | 1 |
| Calvert, L; Claxton, D; Durett, A; Giralt, S; Hamer, J; Kantarjian, H; Khouri, I; Liang, J; Talpaz, M; Tibbits, P | 1 |
| Calvert, L; Deisseroth, AB; Feldman, E; Hester, J; Kantarjian, HM; Korbling, M; Liang, J; Rios, MB; Smith, TL; Talpaz, M | 1 |
| Cortes-Franco, J; Estey, E; Kornblau, SM | 1 |
| Amabile, M; Arpinati, M; Farabegoli, P; Martinelli, G; Testoni, N; Tura, S; Visani, G; Zaccaria, A; Zinzani, PL; Zuffa, E | 1 |
| Beran, M; Cortes, J; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Talpaz, M | 1 |
| Avramis, VI; Dinndorf, PA; Kelleher, JF; Krailo, MD; Liu-Mares, W; Mosher, RB; Reaman, GH; Sato, JK; Seibel, NL; Wiersma, S | 1 |
| Keating, MJ; Li, L; Plunkett, W; Yang, LY | 1 |
| Andreeff, M; Armitage, RJ; Clodi, K; Consoli, U; Palmer, JL; Snell, V; Thomas, EK; Younes, A; Zhao, S | 1 |
| Finney, R; Irving, JA; Lennard, A; Proctor, SJ | 1 |
| Bode, U; Fleischhack, G; Graf, N; Hasan, C; Mann, G | 1 |
| Bahceci, E; Barrett, J; Childs, R; Clave, E; Epperson, D | 1 |
| Estey, E; Feldman, EJ; Kantarjian, HM; Keating, M; Koller, CA; O'Brien, S; Rios, MB | 1 |
| Grigg, A; Roberts, A; Seymour, JF; Szer, J | 1 |
| Nagler, A; Or, R; Slavin, S; Varadi, G | 1 |
| Copia, C; Ferrara, F; Leoni, P; Mele, G; Montillo, M; Morra, E; Nosari, A; Tedeschi, A | 1 |
| Ayres, M; Du, M; Gandhi, V; Hodge, JP; Keating, MJ; O'Brien, S; Plunkett, W; Ramakrishna, P; Rodriguez, CO; Rosner, GL; Weller, S | 1 |
| Battmer, K; Dammann, E; Eder, M; Ganser, A; Hambach, L; Heil, G; Hertenstein, B; Stucki, A | 1 |
| Bornhäuser, M; Ehninger, G; Hertenstein, B; Kiehl, M; Kröger, N; Martin, H; Runde, V; Sayer, HG; Schetelig, J; Schwerdtfeger, R; Siegert, W; Theuser, C | 1 |
| Döhner, H; Gabler, A; Haas, R; Hartmann, F; Hensel, M; Ho, AD; Jung, W; Schlenk, RF; Trümper, L; Weber-Nordt, R | 1 |
8 review(s) available for vidarabine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Coexistence of chronic myeloid leukemia and diffuse large B-cell lymphoma with antecedent chronic lymphocytic leukemia: a case report and review of the literature.
Topics: Antineoplastic Agents; Chromosomes, Human, Pair 12; Cyclin D1; Cyclophosphamide; Disease Progression; Gene Expression Regulation, Neoplastic; Gene Rearrangement; Hematopoietic Stem Cell Transplantation; Humans; In Situ Hybridization, Fluorescence; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Rituximab; Treatment Outcome; Trisomy; Vidarabine | 2018 |
Pseudozyma and other non-Candida opportunistic yeast bloodstream infections in a large stem cell transplant center.
Topics: Adult; Amphotericin B; Antifungal Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cryptococcus; Cytarabine; Dermatomycoses; Echinocandins; Exanthema; Fever; Fungemia; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunocompromised Host; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lipopeptides; Male; Micafungin; Opportunistic Infections; Retrospective Studies; Saccharomyces; Salvage Therapy; Trichosporon; Ustilaginales; Vidarabine; Voriconazole; Yeasts | 2017 |
[A case of chronic myeloid leukemia occurring during treatment for chronic lymphocytic leukemia].
Topics: Aged; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; Female; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms, Second Primary; Piperazines; Pyrimidines; Vidarabine | 2011 |
Purine nucleoside analogues in the treatment of myleoid leukemias.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Clinical Trials as Topic; Cytarabine; Drug Synergism; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Humans; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Pentostatin; Peripheral Blood Stem Cell Transplantation; Remission Induction; Salvage Therapy; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2003 |
[Evidence-based therapy for chronic leukemia].
Topics: Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Enzyme Inhibitors; Evidence-Based Medicine; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Rituximab; Transplantation, Homologous; Vidarabine | 2003 |
Fludarabine in comparison to alkylator-based regimen as induction therapy for chronic lymphocytic leukemia: a systematic review and meta-analysis.
Topics: Alkylating Agents; Antineoplastic Agents; Clinical Trials as Topic; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MEDLINE; Neutrophils; Risk; Time Factors; Treatment Outcome; Vidarabine | 2004 |
[State of the art in the treatment of chronic leukemias].
Topics: Aged; Antineoplastic Agents; Benzamides; Dasatinib; Fusion Proteins, bcr-abl; Genes, abl; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; Survival Analysis; Thiazoles; Vidarabine | 2006 |
Donor cell-derived acute myeloid leukemia developing 14 months after matched unrelated bone marrow transplantation for chronic myeloid leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Bone Marrow Transplantation; Combined Modality Therapy; Cyclosporine; Cystitis; Cytarabine; Cytomegalovirus Infections; DNA, Neoplasm; Female; Foscarnet; Ganciclovir; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Histocompatibility; Humans; Hydroxyurea; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Methotrexate; Mitoxantrone; Neoplasms, Second Primary; Prednisolone; Prostaglandins; Remission Induction; Topotecan; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2001 |
14 trial(s) available for vidarabine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Disease-Free Survival; Gemtuzumab; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Risk Factors; Survival Analysis; Vidarabine; Young Adult | 2012 |
Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Female; Follow-Up Studies; Graft Survival; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Peripheral Blood Stem Cell Transplantation; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Transplantation, Isogeneic; Treatment Outcome; Vidarabine | 2003 |
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Risk Factors; Survival Rate; Vidarabine | 2004 |
Reduced-intensity conditioning using TBI (8 Gy), fludarabine, cyclophosphamide and ATG in elderly CML patients provides excellent results especially when performed in the early course of the disease.
Topics: Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Radiation; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recurrence; Survival Analysis; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2004 |
Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML.
Topics: Adult; Aged; Antineoplastic Agents; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Radiation Dosage; Siblings; Tissue Donors; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2005 |
Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Busulfan; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Recurrence; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2008 |
Treatment of chronic myelogenous leukemia with nucleoside analogs deoxycoformycin and fludarabine.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Drug Administration Schedule; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Count; Middle Aged; Pentostatin; Vidarabine | 1997 |
Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Topics: Acute Disease; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytarabine; Female; Humans; Idarubicin; Infant; Infusions, Intravenous; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1997 |
Molecular remission in Philadelphia-positive adult acute lymphoblastic leukaemia rapidly induced by conventional-dose chemotherapy.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mitoxantrone; Pilot Projects; Polymerase Chain Reaction; Remission Induction; Vidarabine | 1998 |
IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Remission Induction; Vidarabine | 1998 |
A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; DNA Damage; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Salvage Therapy; Treatment Outcome; Vidarabine | 1999 |
Evaluation of the combination of nelarabine and fludarabine in leukemias: clinical response, pharmacokinetics, and pharmacodynamics in leukemia cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arabinonucleotides; Biomarkers; Female; Guanosine Triphosphate; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Prolymphocytic; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Treatment Outcome; Vidarabine | 2001 |
Less intense conditioning with fludarabine, cyclophosphamide, idarubicin and etoposide (FCIE) followed by allogeneic unselected peripheral blood stem cell transplantation in elderly patients with leukemia.
Topics: Adult; Aged; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Cyclosporine; Etoposide; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Chronic-Phase; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Survival Rate; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
40 other study(ies) available for vidarabine and Granulocytic Leukemia, Chronic
| Article | Year |
|---|---|
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cyclophosphamide; Female; Humans; Immunoglobulin Heavy Chains; Immunoglobulin Variable Region; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proportional Hazards Models; Rituximab; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Cyclosporine-related posterior reversible encephalopathy syndrome after cord blood stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Magnetic Resonance Imaging; Posterior Leukoencephalopathy Syndrome; Radiography; Vidarabine; Whole-Body Irradiation | 2013 |
Therapy-related Ph+ leukemia after both bone marrow and mesenchymal stem cell transplantation for hypophosphatasia.
Topics: Bone Marrow Purging; Bone Marrow Transplantation; Child, Preschool; Cyclophosphamide; Female; Follow-Up Studies; Humans; Hypophosphatasia; Infant; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mesenchymal Stem Cell Transplantation; Myeloablative Agonists; Retreatment; Vidarabine | 2013 |
[Therapy-related chronic myelogenous leukemia following RFM therapy in a patient with follicular lymphoma].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma, Follicular; Middle Aged; Mitoxantrone; Rituximab; Vidarabine | 2014 |
Long-Term Outcomes after Treatment with Clofarabine ± Fludarabine with Once-Daily Intravenous Busulfan as Pretransplant Conditioning Therapy for Advanced Myeloid Leukemia and Myelodysplastic Syndrome.
Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Graft Survival; Graft vs Host Disease; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Remission Induction; Survival Analysis; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Survival; Chlorambucil; Cytotoxicity Tests, Immunologic; Dasatinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Synergism; Humans; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Linear Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Pyrimidines; Statistics, Nonparametric; Thiazoles; Tumor Suppressor Protein p53; Vidarabine | 2008 |
A single apheresis procedure in the donor may be enough to complete an allograft using the "Mexican method" of non-ablative allografting.
Topics: Anemia, Aplastic; Antineoplastic Combined Chemotherapy Protocols; Blood Component Removal; Blood Donors; Busulfan; Catheter Ablation; Cost-Benefit Analysis; Cyclophosphamide; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mexico; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2009 |
Combination of fludarabine and imatinib induces apoptosis synergistically through loss of mitochondrial membrane potential and increases in caspase-3 enzyme activity in human K562 chronic myleloid leukemia cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Caspase 3; Cell Death; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Humans; Imatinib Mesylate; Inhibitory Concentration 50; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Mitochondria; Piperazines; Pyrimidines; Vidarabine | 2010 |
Twelfth biannual report of the Cochrane Haematological Malignancies Group--focus on tyrosine kinase inhibitors.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclophosphamide; Dasatinib; Diphosphonates; Disease-Free Survival; Epoetin Alfa; Erythropoietin; Evidence-Based Medicine; Gemtuzumab; Graft vs Host Disease; Hematologic Neoplasms; Hodgkin Disease; Humans; Imatinib Mesylate; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Methotrexate; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Randomized Controlled Trials as Topic; Recombinant Proteins; Rituximab; Stem Cell Transplantation; Thiazoles; Treatment Outcome; Vidarabine | 2011 |
Immune hemolysis after fludarabine-based reduced intensity conditioning and allogeneic PBSC transplantation for CML with minor ABO incompatibility.
Topics: Antineoplastic Agents; Blood Group Incompatibility; Female; Hemolysis; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Peripheral Blood Stem Cell Transplantation; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Dasatinib; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Pyrimidines; Thiazoles; Treatment Outcome; Vidarabine | 2012 |
CML after treatment for lymphoid malignancy: Therapy-related CML or coincidence?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphoma; Male; Neoplasms, Second Primary; Time Factors; Vidarabine | 2002 |
Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction; Survival Analysis; Transplantation, Homologous; Vidarabine | 2003 |
Combination of nonmyeloablative stem cell transplantation and Imatinib in accelerated phase CML.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Combined Modality Therapy; Cytogenetic Analysis; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Piperazines; Pyrimidines; Remission Induction; Stem Cell Transplantation; Vidarabine; Whole-Body Irradiation | 2002 |
The effect of cyclosporin A used alone and in combination with either 2-chlorodeoxyadenosine or fludarabine on normal and chronic myelogenous leukemia progenitors in vitro.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Colony-Forming Units Assay; Cyclosporine; Enzyme Inhibitors; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Vidarabine | 2003 |
Transfusion-free reduced-intensity conditioned allogeneic stem cell transplantation in a Jehovah's witness.
Topics: Adult; Blood Transfusion; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Humans; Immunosuppressive Agents; Jehovah's Witnesses; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Religion and Medicine; Stem Cell Transplantation; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Refusal; Vidarabine | 2003 |
The influence of imatinib mesylate (STI571) used alone or in combination with purine nucleoside analogues on the normal and chronic myelogenous leukaemia progenitor cells in vitro.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Benzamides; Cell Division; Cladribine; Colony-Forming Units Assay; Drug Synergism; Enzyme Inhibitors; Fusion Proteins, bcr-abl; Hematopoietic Stem Cells; Humans; Imatinib Mesylate; In Vitro Techniques; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Middle Aged; Neoplastic Stem Cells; Piperazines; Pyrimidines; Tumor Stem Cell Assay; Vidarabine | 2003 |
Ida-FLAG plus imatinib mesylate-induced molecular remission in a patient with chemoresistant Ph1+ acute myeloid leukemia.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Recombinant Proteins; Salvage Therapy; Treatment Outcome; Vidarabine | 2004 |
BCR-ABL transcripts are early predictors for hematological relapse in chronic myeloid leukemia after hematopoietic cell transplantation with reduced intensity conditioning.
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclosporine; Female; Fusion Proteins, bcr-abl; Hematopoietic Stem Cell Transplantation; Hematopoietic System; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mycophenolic Acid; Neoplasm Recurrence, Local; Prognosis; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Sensitivity and Specificity; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2004 |
FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Topics: Acute Disease; Adolescent; Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Vidarabine | 2005 |
Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
Topics: Acute Disease; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bone Marrow; Clone Cells; Cytarabine; Disease Progression; Fatal Outcome; Fusion Proteins, bcr-abl; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Imatinib Mesylate; In Situ Hybridization, Fluorescence; Interferons; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Neoplastic Stem Cells; Philadelphia Chromosome; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Selection, Genetic; Vidarabine | 2005 |
Gene expression profiles of two accelerations in a CML patient.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mitoxantrone; Multigene Family; Oligonucleotide Array Sequence Analysis; Vidarabine | 2006 |
Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study.
Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Busulfan; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Piperazines; Pyrimidines; Recurrence; Retrospective Studies; Risk Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Czech Republic; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hospital Costs; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Philadelphia Chromosome; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2006 |
Graft rejection and hyperacute graft-versus-host disease in stem cell transplantation from non-inherited maternal-antigen-complementary HLA-mismatched siblings.
Topics: Acute Disease; Adolescent; Adult; Anemia, Aplastic; Blast Crisis; Chimera; Cord Blood Stem Cell Transplantation; Disease Progression; Fatal Outcome; Female; Graft Rejection; Graft vs Host Disease; Histocompatibility; HLA Antigens; Humans; Immunity, Maternally-Acquired; Isoantigens; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Male; Peripheral Blood Stem Cell Transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Remission Induction; Siblings; Tissue Donors; Transplantation Conditioning; Vidarabine | 2007 |
Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia.
Topics: Adolescent; Adult; Aged; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Comparison of myeloablative and nonmyeloablative hematopoietic stem cell transplantation for treatment of chronic myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Antilymphocyte Serum; Busulfan; Child; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Incidence; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Sex Factors; Survival Rate; Transplantation Conditioning; Vidarabine | 2007 |
Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants.
Topics: Adult; Aged; Denmark; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Hospitalization; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Multiple Myeloma; Myelodysplastic Syndromes; Outpatient Clinics, Hospital; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2008 |
FLAG (fludarabine+cytosine arabinoside+G-CSF) induces complete remission in acute-phase chronic myeloid leukaemia: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Marrow; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Vidarabine | 1994 |
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of autolog
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Cyclophosphamide; Daunorubicin; Diploidy; Etoposide; Female; Genetic Markers; Hematopoietic Stem Cells; Humans; Idarubicin; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Accelerated Phase; Leukemia, Myeloid, Chronic-Phase; Male; Middle Aged; Mitoxantrone; Neoplastic Stem Cells; Philadelphia Chromosome; Remission Induction; Survival Rate; Vidarabine; Whole-Body Irradiation | 1995 |
Collection of peripheral-blood diploid cells from chronic myelogenous leukemia patients early in the recovery phase from myelosuppression induced by intensive-dose chemotherapy.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cell Separation; Cytarabine; Daunorubicin; Diploidy; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic Stem Cells; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mitoxantrone; Remission Induction; Vidarabine | 1995 |
Neurotoxicity associated with fludarabine and cytosine arabinoside chemotherapy for acute leukemia and myelodysplasia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Cytarabine; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Myelodysplastic Syndromes; Nervous System Diseases; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Vidarabine | 1993 |
FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow; Bone Marrow Transplantation; Chromosome Aberrations; Combined Modality Therapy; Cytarabine; Disease Progression; Granulocyte Colony-Stimulating Factor; Humans; Hydroxyurea; Immunologic Factors; Interferon-alpha; Karyotyping; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Mercaptopurine; Middle Aged; Mitoxantrone; Remission Induction; Vidarabine | 1996 |
Fludarabine-mediated repair inhibition of cisplatin-induced DNA lesions in human chronic myelogenous leukemia-blast crisis K562 cells: induction of synergistic cytotoxicity independent of reversal of apoptosis resistance.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Southern; Cell Count; Cisplatin; DNA Damage; DNA Repair; DNA, Neoplasm; Drug Interactions; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Tumor Cells, Cultured; Tumor Stem Cell Assay; Vidarabine; Xeroderma Pigmentosum | 1997 |
Elevated levels of biologically active soluble CD40 ligand in the serum of patients with chronic lymphocytic leukaemia.
Topics: Adult; Apoptosis; Blood Platelets; CD40 Ligand; Dose-Response Relationship, Drug; Enzyme-Linked Immunosorbent Assay; Fas Ligand Protein; Female; Humans; Immunosuppressive Agents; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocyte Count; Membrane Glycoproteins; Up-Regulation; Vidarabine | 1998 |
Molecular remission of chronic myeloid leukaemia following a non-myeloablative allogeneic peripheral blood stem cell transplant: in vivo and in vitro evidence for a graft-versus-leukaemia effect.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Graft vs Leukemia Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine | 1999 |
Mini-allografts' for haematological malignancies: an alternative to conventional myeloablative marrow transplantation.
Topics: Adult; Bone Marrow Transplantation; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Vidarabine | 1999 |
Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis.
Topics: Adult; Antineoplastic Agents; Arthritis, Psoriatic; Autoimmunity; Busulfan; Graft vs Host Disease; Graft vs Leukemia Effect; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lymphocytes; Male; Psoriasis; Reverse Transcriptase Polymerase Chain Reaction; Vidarabine | 2000 |
Treatment of chronic myeloid leukemia in the blastic phase with fludarabine, cytosine arabinoside and G-CSF (FLAG).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Marrow Transplantation; Cytarabine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Remission Induction; Vidarabine | 2000 |
Dose-reduced conditioning for allografting in 44 patients with chronic myeloid leukaemia: a retrospective analysis.
Topics: Adult; Aged; Antigens, CD34; Busulfan; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Interferon-alpha; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Risk Factors; Survival Rate; Transplantation Conditioning; Vidarabine | 2001 |